MarketInOut Stock Screener Log In | Sign Up
 

Biomea Fusion Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/06/2026 13:29
Biomea Fusion Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization93.99 mln
Float67.58 mln
Earnings Date11/03/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

4 / 100
Severely lagging

Debt / Equity

0.07
Debt-free

ROE

-157
Deeply negative

ROA

-60.22
Deeply negative

Business Description

Biomea Fusion is a US-based medical research company working to bring new treatments to people living with diabetes and obesity. Founded in 2017 and based in San Carlos, California, the company is developing pills that work by blocking a specific protein in the body to influence how cells grow and function. Its primary drug in development, icovamenib, is taken by mouth and targets a protein called menin, which plays a key role in regulating genes and cell activity.

Key Fundamentals

EPS-0.29
ROE-157
ROIC-862
ROA-60.22
EBITDA, mln-32.03
EV / EBITDA-1.93
EV / EBIT-1.90

Quote Details

Last 1.25
Change -0.05 (-3.85%)
Open 1.28
Volume 373,460
Turnover 466,825
Average Volume 1,973,289

Financial Ratios

Leverage Ratio3.04
Current Ratio3.48
Price / Book7.82
Price / Tangible Book7.82
Debt / Equity0.07

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio5.86
Short % of Float22.24

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -0.79% 32 / 100   
1 Month -38.42% 4 / 100   
2 Months -14.97% 26 / 100   
6 Months -34.21% 14 / 100   
1 Year -41.86% 20 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us